Refine
Year of publication
Document Type
- Article (43)
- Doctoral Thesis (42)
Has Fulltext
- yes (85)
Is part of the Bibliography
- no (85)
Keywords
- - (38)
- Streptococcus pneumoniae (7)
- Saccharomyces cerevisiae (6)
- Arxula adeninivorans (5)
- Enzym (4)
- Hefe (4)
- proteomics (4)
- Biochemische Analyse (3)
- Pneumokokken (3)
- Virulenz (3)
Institute
- Institut für Mikrobiologie - Abteilung für Genetik & Biochemie (85) (remove)
Publisher
- Frontiers Media S.A. (20)
- MDPI (14)
- S. Karger AG (3)
- American Society for Microbiology (ASM) (1)
- Nature Publishing Group (1)
- Public Library of Science (PLoS) (1)
- Wiley (1)
Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases. Several proteasome inhibitors are approved for treating hematological cancers. However, their side effects impede their efficacy and broader therapeutic applications. Therefore, understanding the biology of the different proteasome complexes present in the cell is crucial for developing tailor-made inhibitors against specific proteasome complexes. Here, we will discuss the structure, biology, and function of the alternative Proteasome Activator 200 (PA200), also known as PSME4, and summarize the current evidence for its dysregulation in different human diseases. We hereby aim to stimulate research on this enigmatic proteasome regulator that has the potential to serve as a therapeutic target in cancer.